SAM
BLRX

Sectoral Asset Management’s BioLineRX BLRX Stock Holding History

Sectoral Asset Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-297
Closed -$65K – 66
2019
Q2 		$65K Hold
297
– – 0.01% 87
2019
Q1 		$77K Sell
297
-33
-10% -$9.61K 0.01% 101
2018
Q4 		$87K Hold
330
– – 0.01% 96
2018
Q3 		$212K Buy
+330
New +$182K 0.02% 131

Other funds holding BLRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sectoral Asset Management's BLRX Position: Q3 2019 in Review

Sectoral Asset Management sold out of BioLineRX (BLRX) in Q3 2019, closing a stake of 297 shares — an estimated $65K sold.

Sectoral Asset Management first reported a position in BLRX in Q3 2018 and held it in 4 quarters. The position peaked at $212K in Q3 2018. 15 funds tracked by Wall St. Rank hold BLRX as of Q3 2019.

  • Sectoral Asset Management reported no remaining BioLineRX position as of Q3 2019 after selling out during the quarter.
  • Sectoral Asset Management sold 297 BioLineRX shares in Q3 2019, an estimated $65K.
  • Sectoral Asset Management first reported a position in BioLineRX in Q3 2018 and held it in 4 quarters.
  • Sectoral Asset Management's BioLineRX position peaked at $212K in Q3 2018.
  • 15 funds tracked by Wall St. Rank held BioLineRX as of Q3 2019.

Based on Sectoral Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.